NVO
Novo Nordisk A/S
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 45.14
Buy <=wait / entry
USD 37.33
Trim >=take some off
USD 46.00
Thesis breakThe thesis is invalidated if 2026 adjusted sales or operating profit guidance is...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 23% | 100 / 100 | 23.0 |
| Base case | 47% | 62 / 100 | 29.1 |
| Bear case | 30% | 10 / 100 | 3.0 |
| Weighted conviction | 49 / 100 - SPECULATIVE BUY | ||
Top risks
- M&A activity: Novo Nordisk announced acquisition of Akero Therapeutics for $4.7 billion cash plus $0.5 billion CVR to add efruxifermin for MASH treatment
- Strategic licensing deals: Partnership with Vivtex for up to $2.1 billion in oral obesity drugs and agreement with Veru for obesity combination therapy trial
- Earnings or guidance changes: Company raised 2026 outlook but expects adjusted sales down 6% to flat and operating profit down 6% to flat, citing US sales decline